Chronic gut inflammation disposes to an increased risk of colitis-associated cancer. Chemoprevention is an attractive complementary strategy. We aimed to evaluate the chemopreventive effects of M10, a novel derivative of Myricetin, in the murine azoxymethane/dextran sodium sulfate model. Oral administration of M10 at 50-100 mg/kg once a day for consecutive 12 weeks significantly prevented ulcerative colitis (UC) and colorectal tumor. Pathological analysis of intestines showed that M10 reduced the degree of chronic inflammation and prevented the progression of colorectal tumorigenesis. Flow cytometry analysis of the immunocytes isolated from intraepithelial and lamina propria showed that M10 prevented the infiltration of myeloid-derived suppressor cells and increased CD8 + T and CD4 + T cells in colorectal tissues. Enzyme-linked immunosorbent analysis revealed the reduction of pro-inflammatory mediators granulocytemacrophage colony-stimulating factor/macrophage colony-stimulating factor, IL-6 and TNF-α in colonic mucosa. Western blot assay also showed M10 prevention of the NF-κB/IL-6/STAT3 pathways and the biomarkers of inflammation and colorectal tumorigenesis. Electron microscopy analysis revealed that M10 prevent robust endoplasmic reticulum (ER) stressinduced autophagy in inflamed colonic mucosal cells. In conclusion, oral administration of Myricetin derivative M10 exerts chemoprevention of UC and colorectal tumor in mice. The mechanism of chemoprevention is associated with the reduction of biomarkers of chronic inflammation and proliferation through attenuating robust ER stress in inflamed colonic mucosal cells. M10 exerts chemoprevention activity without evidence of toxicity in mice. These results justify further evaluation of M10 in clinical trials. M10 could develop a promising regimen in the chemoprevention of colitis and colorectal cancer.
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancerrelated deaths worldwide, and its burden is expected to increase by 60% to more than 2.2 million new cases by 2030 (1) . CRC includes hereditary, sporadic and colitis-associated cancer (CAC). Although numerous factors, such as inherited genes, environmental exposures and diet, colonic chronic inflammation have been determined the most direct link to CRC. Colonic chronic inflammation, including ulcerative colitis (UC) and Crohn's disease, is a complex, relapsing and remitting inflammatory conditions of intestinal tract (2) . Although CAC accounts for 2-5% of all CRCs, CAC is responsible for 10-15% of deaths in the patients with UC. The increase of inflammation degree and disease duration could largely increase the risk of CAC (3) . Current therapeutic drugs for the treatment of colitis such as corticosteroids, immunomodulators, antibiotics and aminosalicylates are based on the mitigation of symptoms, including inflammatory remission and healing of mucosal manifestations. However, the results of these drugs are uncertain, as response to the treatment often diminishes over time, resulting in disease complications. The clinical therapies for CRC are surgery, chemotherapy and radiation therapy. These therapies are of limited efficacy in latestage CRC patients. Nowadays, chemoprevention is an attractive complementary strategy, and drugs without toxicity and better efficacy are in high demand for the treatment of colonic chronic inflammation and chemoprevention of colorectal tumorigenesis.
On the basis of preclinical data, Myricetin, a widespread naturally occurring flavonoid, has the potential to meet these criteria. Myricetin has multiple biological activities, such as antioxidant, anti-inflammatory, anticarcinogenic and antiproliferative effects (4) . In our previous study, we found that Myricetin prevented intestinal tumorigenesis through inhibition of the Wnt/β-catenin pathway in the adenomatous polyposis coli multiple intestinal neoplasia (APC Min/+ ) mice (5) . However, Myricetin exhibits substantial limitations, such as complex isolation procedures, poor water solubility (<100 ng/ml) and low bioavailability (6) . The synthesis of derivatives of Myricetin is thus needed. In our group, we had designed and synthesized a series of novel compounds based on Myricetin (Supplementary Figure S1A , available at Carcinogenesis Online). The chemical structures of the compounds named M3, M4, M8, M9 and M10 were identified (Supplementary Figure S1B, available at Carcinogenesis Online). The following screening assays showed that these compounds demonstrated stronger activity of prevention colonic chronic inflammation than the parent Myricetin in the dextran sulfate sodium (DSS) model (Supplementary Figure S2 , available at Carcinogenesis Online). Among these compounds, M10 displayed the highest activity of prevention UC. Chemically, M10 was designed based on Myricetin by adding a hydrophilic group. M10 has thus a good water solubility (>0.1 g/ml). Its median lethal dose (LD50) is >5 g/kg in mice. M10 appears to have a good safety profile as an oral chemoprevention agent; however, before entering clinical trials, in vivo chemoprevention activity needs to be demonstrated. Because Aspirin has been considered effective to reduce the risk of CRC incidence, we decided to compare the efficacy of M10 with Aspirin in their activities of anti-inflammation and prevention of colorectal tumorigenesis.
Materials and methods

Animal care and diet
Animal experiments were approved by Animal Welfare Committee of Capital Medical University. C57BL/6 mice were purchased from Charles River Laboratories (Beijing, China). Mice were caged under a controlled room temperature, humidity and light (12/12 h light/dark cycle) and allowed unrestricted access to standard mouse chow containing 52% carbohydrate, 12% fat, 23% protein, 4% fiber, 6% ash and 3% moisture and tap water (7) .
Chemicals
The derivatives of Myricetin were provided by Dr Li in Marine Biomedical Research Institute of Qingdao. Chemical structures of M10 (purity ≥ 98%) and the parent Myricetin are shown in Supplementary Figure S1B , available at Carcinogenesis Online. Myricetin (purity ≥ 98%) and Aspirin (purity ≥ 99%) were purchased from Sigma-Aldrich (St. Louis, MO).
Animal model of colitis and CAC and the pharmacological treatment protocol
A total of 70 mice (6-8 weeks, male) were randomly divided into following groups-Group 1: normal control mice (oral water); Group 2: azoxymethane (AOM)/DSS-induced colitis and CAC model mice (oral water); Group 3: mice exposed to AOM/DSS treated with 100 mg/kg of Aspirin; Group 4: mice exposed to AOM/DSS treated with 100 mg/kg of Myricetin; Group 5-7: mice exposed to AOM/DSS treated with 25, 50 and 100 mg/kg of M10, respectively. Briefly, mice were intraperitoneally injected with 10 mg/kg AOM (Sigma-Aldrich). After 7 days, mice were received water containing 1.0% DSS (molecular weight 36 000-50 000, MP Biomedicals, LLC, Santa Ana, CA) for another 7 days. Mice were then given regular water for 14 days, followed by three additional DSS cycles.
The pharmacological treatments were performed by gavage once a day for consecutive 12 weeks from the second day after AOM injection. Mice were weighed twice a week and observed daily for any signs of illness. The pathological process of AOM/DSS-induced UC was assessed by disease activity index (DAI) according to a standard scoring system (8) .
Tissue processing and colonic cancer scoring
After 12 weeks' treatment, mice were sacrificed and blood was obtained from postorbital venous plexus. Whole colorectal tissues were removed, and macroscopic tumors were counted and measured with digital calipers based on diameter into <1, 1-5 and >5 mm. The portions of colonic tissues were either snap-frozen in liquid nitrogen or placed in formalin for histopathology/immunohistochemical (IHC) analysis.
Isolation of immunocytes and flow cytometry analysis
Peripheral blood and colonic immunocytes were isolated as described previously (9) . Colonic tissues were carefully separated and cut into small pieces (2-3 mm). Intraepithelial immunocytes were separated by incubating tissues in 0.015% dithioerythritol (Sigma-Aldrich). For isolating immunocytes of lamina propria, remaining tissue was incubated with EDTA and then digested by digestion buffer (RPMI medium containing 5% FBS and 200 U/ml of collagenase) (Gibco). Immunocytes were finally enriched using discontinuous (44 and 67%) percoll (GE) separation method. Immunocytes were stained with anti-CD11b + Ly6C + (101206, 128008, Biolegend) to determine monocytic myeloid-derived suppressor cells (M-MDSCs), anti-CD11b + Ly6G + (101206, 1127627, Biolegend) to granulocytic MDSCs (G-MDSCs). Anti-CD3 + /CD4 + (100234, 100424, Biolegend) and anti-CD3 + /CD8 + (100234, 100730, Biolegend) were used to determine T lymphocytes. Anti-CD11b + F4/80 (101206, 123128, Biolegend) stained macrophages (10) . Stained immunocytes were analyzed by a flow cytometer (BD LSRFortessa). Flow cytometric profiles were analyzed by counting 20 000 events using Kaluza software program (Beckman Coulter). 
Abbreviations
Electron microscopic analysis
Electron microscopic assay was performed in fresh colonic tissues to analyze colonic structures, and autophagy described elsewhere.
ELISA assay
Colonic polyps and mucosa (100 mg) were homogenized in 1 ml homogenization buffer (0.1 mol/l phosphate buffer, pH 7.4 containing 1 mmol/l EDTA and 10 μmol/l indomethacin) with polytron-type homogenizer. The homogenates were centrifuged at 14,000g for 10 min at 4°C. The supernatants were aliquoted and stored at −80°C. Levels of TNF-α, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) were determined by using available sandwich enzyme-linked immunosorbent (ELISA) kits according to manufacturer's protocols. TNF-α kit (500850) and IL-6 kit (583371) were purchased from Cayman Chemical (Ann Arbor, MI). GM-CSF kit (CSB-E04569m) and M-CSF kit (CSB-E04659m) were provided by CUSABIO (Wuhan, Hubei, China).
Western blotting assay
Western blotting assay was performed to determine the levels of the following proteins. Equal amounts of proteins from supernatant of colonic mucosa were resolved by SDS-PAGE and transferred to PVDF membranes. After blocking in 5% non-fat milk for 1 h, membranes were immunoblotted overnight at 4°C with following primary antibodies. The bound antibodies were visualized using an enhanced chemiluminescence reagent and quantified by densitometry using FluorChem FC3 image analyzer (Molecular Devices). Densitometric analyses of bands were adjusted with β-actin. Primary antibodies included GRP78 (ab108615, Abcam), ATF6 (65880), eIF2α (3294), P-eIF2α (3398), IRE1α (3294), mTOR (2983), P-mTOR (5536), AKT (9272) 
Statistical analysis
Data were described as mean ± SD. Comparison multiple groups were analyzed by one-way analysis of variance, and multiple between-group comparisons were performed using SNK (Student-Newman-Keuls) method.
Comparison between two groups was conducted by two-tailed Student's t-test. A P value <0.05 was considered statistically significant.
Results
M10 strongly prevented AOM/DSS-induced UC and colorectal tumor
Mice exposed to AOM/DSS exhibited serious symptom of colitis such as diarrhea, hair bristling, anal prolapses due to ulcerative inflammation in the distal colon. Body weight loss and bloody stools started from day 4. By day 8, mice lost 6.7% of their starting body weight ( Figure 1A , P < 0.05). Disease severity scored by DAI reached the highest level on day 7 in fourth DSS cycle ( Figure 1B ). M10 strongly prevented AOM/DSS-induced UC. We observed less severity of ulcerative inflammation in M10-treated mice, showing the prevention of bloody stools (P = 0.041 versus model mice) and body weight loss (P < 0.05 versus model mice). M10 significantly reduced the DAI ( Figure 1B , P < 0.05 versus model mice). In contrast, the parent Myricetin and control drug Aspirin had only a mild inhibitory effect on DAI ( Figure 1B , P > 0.05 versus model mice). AOM/DSS-induced inflammation and tumor resulted in shortening of colorectal length. The average length of colon was 9.9 cm in normal mice. Model mice presented colorectal length by 7.8 cm, while 8.7-8.8 cm in M10-treated mice ( Figure 1C , P < 0.05-P < 0.01). Histopathologic analysis of colonic tissues revealed severe inflammatory lesions in 100% of model mice but not in M10-treated mice ( Figure 1D ). Observed inflammatory lesions included different degrees of structural changes ranging from swelling and degeneration of villous epithelia to extensive denudation and collapse of villi, surface erosion with exuberant inflammatory exudate, patchy reepithelization, lamina propria fibrosis with acute and chronic inflammatory immunocytes infiltration and submucosa edema ( Figure 1D-b) . M10-treated mice demonstrated the integrity and normal structure of colon tissue ( Figure 1D -e-g). M10 significantly reduced inflammation degree, and its activity was much higher than that of the parent Myricetin and control drug Aspirin ( Figure 1D , P < 0.01-P < 0.001 between M10 and Myricetin or Aspirin).
Further analysis showed that AOM/DSS induced colonic tumor by 100% in model mice, whereas by 12.5, 1.5 and 0%, respectively, in M10-treated mice by 25, 50 and 100 mg/kg (Figure 2A Histopathological analysis showed that model mice presented advanced tubular adenoma, showing focal high-grade dysplasia with marked nuclear pleomorphism, lack of nuclear polarity, frequent mitoses and architectural distortion ( Figure 2C-b) . Gross ulceration was frequently observed in model mice. M10 dose-dependently lessened the severity of colonic lesions and tumorigenesis ( Figure 2C-e-g ). Mice treated by 50 and 100 mg/ kg of M10 achieved the integrity of colonic epithelium and normal goblet cells ( Figure 2C-e-g ). In contrast, Myricetin had mild restoring effects on colonic structures ( Figure 2C-d) . There is a lack of evidence to show a preventative effect of Aspirin on colorectal tissue lesions and tumorigenesis ( Figure 2C-c) .
IHC analysis of colonic tissues showed that M10 strongly reduced AOM/DSS-induced high expression of Ki-67 ( Figure 2D e-g), whereas Aspirin and Myricetin weakly inhibited Ki-67 level in colonic epithelium ( Figure 2D-c-d) .
M10 prevented the infiltration of MDSCs and pro-inflammatory mediators GM-CSF and M-CSF, IL-6 and TNF-α in colonic tissues and blood
We analyzed the profiles of immunocytes in colonic tissues and blood. In mice, MDSCs are broadly defined as CD11b Since MDSCs are a major source of inflammatory mediators (12), we examined levels of inflammatory mediators in inflamed colonic mucosa and tumors. As expected, M10 strongly reduced the levels of M-CSF ( Figure 3E , P < 0.01 versus model mice), GM-CSF ( Figure 3F , P < 0.01 versus model mice), IL-6 ( Figure 3G , P < 0.001 versus model mice) and TNF-α ( Figure 3H , P < 0.001 versus model mice). Myricetin and Aspirin also inhibited IL-6 and TNF-α (P < 0.01 versus model mice) but not M-CSF and GM-CSF (P > 0.05 versus model mice).
M10 significantly increased CD8 + T and CD4 + T lymphocytes while reduced macrophagy
In model mice, both CD4 + T and CD8 + T lymphocytes were strongly reduced in blood and colonic tissues (P < 0.001 versus normal mice). M10 increased CD8
+ T and CD4 + T lymphocytes scoring of colitis from normal mice (a; ×100 (above), ×400 (bottom); colitis model ( Figure 1D-b) ; Aspirin-treated mice (c); Myricetin-treated mice (d) and M10-treated mice by 25, 50 and 100 mg/kg (e-g). Each dot represents eight mice (n = 8). # P < 0.05, ### P < 0.001 between normal and model mice. *P < 0.05, **P < 0.01, ***P < 0.001 between model and drug-treated mice. & P < 0.05, && P < 0.01, &&& P < 0.001 between M10 and Myricetin.
both in blood and colonic tissues. Flow cytometry analysis of blood showed a significant increase of CD4 + T ( Figure 4A , P < 0.01 versus model mice) and CD8 + T lymphocytes ( Figure 4B , P < 0.05 versus model mice). IHC analysis also showed an increase of CD4 + T ( Figure 4C -e-g) and CD8 + T cells ( Figure 4D -e-g) in colonic tissues. Myricetin weakly increased CD4 + T and CD8 + T lymphocytes in colonic tissues. Aspirin did not have the activity of increasing CD4 + T and CD8 + T lymphocytes in blood and colonic tissues ( Figure 4A-D) .
During colitis, high level of IL-6 stimulates large number of macrophages in inflamed colon and tumors (12) . We analyzed the profile of macrophages by flow cytometry assay. M10 dosedependently reduced the infiltration of macrophages in intraepithelial and lamina propria ( Figure 4F , P < 0.001 versus model mice). Myricetin and Aspirin also had the activity of reducing macrophages in colonic tissues (P < 0.05 versus model mice).
M10 prevented UC and tumor through attenuating robust ER stress
Upon endoplasmic reticulum (ER) stress, unfolded and misfolded proteins bind and sequester resident ER chaperone GRP78, thereby activating unfolded protein response (UPR) (13).
Robust ER stress produced misfolded proteins beyond tolerable threshold; the ER-resident sensors trigger an UPR to transcriptionally and translationally improve the ER protein-folding capacity. UPR comprises three parallel signaling branches: PKR-like ER kinase (PERK)-eukaryotic translation initiation factor 2α (eIF2α), inositol-requiring enzyme 1α (IRE1α) and ATF6. In model mice, the presence of robust ER stress was validated by ultrastructural analysis of ER under electron microscopy ( Figure 5A ). ER lumen was expanded and broken up into short lengths with numerous swellings and vacuole-like structures. Very little of ribosomes attached ER, and there were few free ribosomes in the cytoplasm (Figure 5A-b) . M10 prevented AOM/DSS-induced ER stress. In M10-treated mice, the ER lumen was showed integrity with continuous ER lumen and normal structures with extensive parallel membranes. Large numbers of ribosomes were frequently observed attached to the ER as well as free in the cytoplasm ( Figure 5A-e-g ). The restoring effect of M10 on the ER structure was more visible than Aspirin-( Figure 5A-c) and Myricetin-treated mice ( Figure 5A-d) .
Furthermore, M10 suppressed the secretion of ER-resident sensors in colonic mucosal cells. We analyzed levels of GRP78 and its major ER-spanning transmembrane proteins, ATF6, Myricetin also reduced robust ER stress-induced secretion of the ER-resident sensors (P < 0.05 versus model mice) but not Aspirin. IHC analysis of colonic tissues further confirmed the prevention effect of M10 on GRP78 in inflamed colonic mucosa ( Figure 5C ). M10 prevented robust ER stress-induced activation of NF-κB/IL-6/STAT3 and mTOR signaling pathways. In contrast, Myricetin and Aspirin weakly prevented these signaling cascades in inflamed colonic mucosa and colonic cancer cells (Figure 5D-F) .
M10 inhibited robust ER stress-mediated autophagy and apoptosis in colonic mucosal cells
Continuous AOM/DSS induces accumulation of misfolded proteins beyond correction effects, leading to mucosal cells apoptosis, while robust ER stress enhances cell survival through sustaining autophagy. Activation of autophagy could support cells to adapt the ER stress-induced hostile environment, leading tumorigenesis (14) . In model mice, the presence of robust ER stress-induced autophagy was observed under electron microscopy. Double-membrane autophagy vesicles were frequently observed in mucosal cells (Figure 6A-b) . In contrast, there are few autophagy vesicles in M10-treated mice ( Figure 6A-e-g ). blood (B) . Flow cytometry analyzed G-MDSCs in colonic intraepithelial and lamina propria (C) and blood (D). ELISA assay determined levels of M-CSF (E), GM-CSF (F), IL-6 (G) and TNF-α (H) in supernatant of colonic mucosa. Each dot represents eight mice (n = 8). # P < 0.05, ## P < 0.01, ### P < 0.001 between normal and model mice. *P < 0.05, **P < 0.01, ***P < 0.001 between model and drug-treated mice. & P < 0.05, && P < 0.01, &&& P < 0.001 between M10 and Myricetin.
Aspirin and Myricetin mildly inhibited autophagy vesicles in colonic mucosal cells ( Figure 6A-c-d) .
Upon phagophore, a conjugate of ATG3, ATG5, ATG7, ATG12 and ATG16 may multimerize with ATG16L1 to form a complex of autophagosomes and then lapidates LC3 (LC3-II) (15) . M10 significantly inhibited the formation of autophagosomes ( Figure 6B ) and LC3-II (P < 0.05) and Bcelin-1 (P < 0.05) as compared with model mice (Figure 6C ). Because AOM/DSS induced colorectal tumor in 100% of mice, we thus suggest that the increase of autophagy occurs in inflamed epithelium and colorectal tumor. M10 inhibited robust ER stress-mediated autophagy, leading an inhibition of colorectal tumorigenesis. In contrast, Aspirin and Myricetin did not significantly inhibit ER stress-mediated autophagy ( Figure 6C , P > 0.05 versus model mice; P < 0.05 between M10 and Myricetin or Aspirin).
Robust ER stress also induced colonic mucosal cells to apoptosis (16) . Model mice exhibited frequent apoptotic cells in colonic epithelium, showing compacted and segregated chromatins against nuclear envelope, and membranes enclosed with cytoplasmic blebs (Figure 6D-b) . M10-treated mice maintained apparently integrity and normal epithelium structures. Compacted and segregated chromatins and membranes enclosed with cytoplasmic blebs were not as frequently as in model mice ( Figure 6D-e-g ). TUNEL analysis further showed the inhibitory effect of M10 on apoptosis in colonic epithelium ( Figure 6E ). Under hostile environmental stresses, the stressactivated protein kinase/Jun-amino-terminal kinases (SAPK/ JNK) were preferentially activated, leading to activation of downstream signaling BAX and Caspase-3 (17) . M10 significantly reduced the levels of SAPK/JNK (P < 0.01 versus model mice), BAX (P < 0.01 versus model mice) and Caspase-3 (P < 0.05-P < 0.01 versus model mice). Although M10 did not affect level of BCL-2 (P > 0.05 versus model mice), the ratio of BAX and BCL-2 was reduced significantly in M10-treated mice (P < 0.01 versus model mice). Aspirin and Myricetin mildly prevented ER stress-induced apoptotic cascades in inflamed epithelium and colorectal tumor cells ( Figure 6F , P < 0.05 versus model mice; P < 0.05 between M10 and Myricetin or Aspirin). dot represents eight mice (n = 8). # P < 0.05, ## P < 0.001 between normal and model mice. *P < 0.05, ** P < 0.01, *** P < 0.001 between model and drug-treated mice. & P < 0.05, && P < 0.01, &&& P < 0.001 between M10 and Myricetin.
Discussion
An ideal chemoprevention agent for the treatment of colitis is orally local contact to inflamed colon tissues while exerting no side effects. Chemically, M10 was designed based on Myricetin by adding a hydrophilic group. This chemical modification might improve the solubility of M10 to enhance its biological activities and enlarge its application range. In pilot study, oral administration of M10 in rat did not have evidence of absorption into circulatory system (data not shown). We thus suggest that the inhibitory effects of M10 on colitis and colorectal tumor might associate with its local contact to the intestinal tissue rather than getting absorbed into systemic circuit. The results in the present study confirm that M10 possesses higher efficacy of chemoprevention than that of the parent Myricetin in the murine AOM/DSS model. Long-term use of M10 did not induce side effects, implying that M10 did not absorb into systemic circuit. The inhibitory effects of M10 on the biomarkers in inflammation and tumorigenesis are greater than Myricetin and control drug Aspirin. These studies provide a foundation for future chemoprevention trials with this novel agent. However, before entering clinical trials, in vivo pharmacokinetic analysis needs to be demonstrated. Chemoprevention refers to the use of an anti-inflammatory therapy which prevents tumorigenesis through improving colorectal mucosal healing. M10 strongly prevented the infiltration of MDSCs in intraepithelial and lamina propria of colorectal tissue. MDSCs are major components of inflammatory tumor microenvironment. During chronic inflammation, and more so in tumorigenesis, there are various activated immune cells in which there is a vicious cycle of tissue destruction and repair due to either irremovable injurious stimuli or a dysfunction in any component of normal inflammatory response. Persistent increased MDSCs could inhibit T-cell infiltration, while the function of macrophages in antitumorigenesis or protumorigenesis has still been controversial (18) . Anyway, activated MDSCs and reduced T cells and macrophages together have been determined to contribute downregulation of immune responses in colonic epithelial barrier (18) . Furthermore, MDSCs largely produce GM-CSF and M-CSF. Importantly, a reciprocal regulation was found between MDSCs and their products GM-CSF and M-CSF in inflamed colonic intraepithelial and lamina propria and cancer tissues (19) . Emerging evidence suggests a central role in GM-CSF and M-CSF in the pathogenesis of colitis, resulting in a complex, chronic, relapsing and remitting inflammatory condition in colonic tissues (20) . MDSCs are also major sources of IL-6 and TNF-α which are involved in IL-6/STAT3 pathway playing an immunosuppressive function in tumor microenvironment (21, 22) . Our present study confirmed that M10 prevented colitis and tumor through inhibiting the accumulation of MDSCs in tumor microenvironment.
Malignant cells could utilize diverse strategies that enable them to thrive under adverse condition. It is widely studied that both robust ER stress and UPR activation are involved in colitis and tumorigenesis. In normal condition, ER could regulate cellintrinsic and cell-extrinsic stresses to adaptive ER protein-folding machinery readily handles secretion pathway requirements. During colitis, numerous environmental, physiological and pathological insults disrupt the steady state of ER protein-folding environment to cause accumulation of misfolding protein beyond the tolerable threshold, thus the ER-resident sensors trigger UPR to transcriptionally improve ER protein-folding capacity (23) . If these corrective effects are insufficient, colonic mucosal cells will undergo apoptosis. If cells successfully limit pro-apoptotic UPR outputs, the ER stress confers survival advantages to tumorigenesis (24) . Sustained activation of robust ER stress sensors could thus endow tumorigenesis. Therapeutic strategies to control robust ER stress are thus effective for the prevention of colitis and tumorigenesis (25) . In colitis and CAC model, continuous AOM/DSS produced robust ER stress, prolonging UPR activation owing to unresolved misfolding protein, leading mucosal epithelial cells to transform tumorigenesis through the mechanism of UPR activation as a survival strategy through autophagy, while sublethal ER stress caused colonic mucosal cell lesion and death through activation of apoptosis. In human, a number of pathophysiological conditions, such as high-fat and high-sucrose diet, viral and parasitic chronic infections, could disrupt intestinal homeostasis and thus associate with excessive and/or persistent robust ER stress (25, 26) . Persistent robust ER stress contributes to the pathophysiology both by inciting cell death and by leading to dysregulation of redox balance, inflammatory cascades and other physiological processes (27) . Because AOM/DSS induced colorectal tumor in 100% of mice, we thus suggest that autophagy occurs in tumor cells. In our present study, M10 strongly reduced robust ER stress-mediated autophagy, thus preventing colorectal tumor.
Under ER stress, cells might constantly adjust sizes and shapes of their organelles according to need. In AOM/DSS model, robust ER stress induced ER expansion. ER expansion generated a double-membrane structure called phagophore. Upon phagophore, ATG16L1 forms a complex with an ATG5-ATG12 conjugate, which multimerizes and then lipidates LC3 (LC3-II) (25) . Autophagy could counterbalance ER expansion during UPR, facilitating cell survival and tumorigenesis (28) . Accumulating reports revealed that ER expansion is mainly regulated by three major ER-spanning transmembrane proteins: IRE1α, PERK and ATF6 (29) . These sensors are bound intraluminally by chaperone GRP78, which locks them in monomeric and inactive state (30) . If misfolded proteins exceed folding capacity of ER-resident chaperones, GRP78 will dissociate from IRE1α, PERK and ATF6. These ER-resident sensors subsequently drive mutually reinforcing signaling pathways to correct misfolded proteins. If the burden can be reduced quickly, colonic mucosal cells successfully adapt to the insult to survival through autophagy, whereas insufficient clearance results in apoptotic cell death. AOM/DSS induced colorectal tumor in 100% of mice, thus autophagy occurs in tumor cells. Simultaneously, robust ER stress-induced mucosal cells to apoptosis further exacerbated inflammatory lesion in colonic tissues. AOM/DSS-induced colitis and colorectal tumor is thus a collection of signaling pathways that involved in autophagy in tumor cells and apoptosis in normal mucosal cells. Targeting UPR and robust ER stress responses is thus an important therapeutic rationale for the prevention of colorectal tumorigenesis. M10 reduced robust ER stress-induced autophagy, preventing chronic inflammation and colorectal tumorigenesis. In the same time, M10 inhibited ER stress-mediated apoptosis, thus protecting intestinal mucosal structure from inflammatory lesions.
Investigation of pathogenic mechanisms suggested a complex signaling pathway revolving around ER stress and UPR. In this study, all three major ER sensors are found cross-talk between ER stress and mTOR signaling. In CAC model, it is plausible that mTOR may phosphorylate a key protein PERK in ER stress pathway and then dissociate three ER sensors to function their UPR pathway. Alternatively, mTOR may contribute to ER stress by inducing new protein synthesis and therefore triggering further protein overload in the ER lumen. We thus suggest that M10 directly regulate mTOR expression probable, which further inhibit the ER stress-induced UPR pathway.
In colitis and CAC model, all three major ER sensors augment the NF-κB/IL-6/STAT3 cascades, a master transcriptional regulator of pro-inflammatory pathway in colitis and tumorigenesis. NF-κB could promote cell survival pathway that is required for the proliferation of premalignant cells (31) . Activation of NF-κB in mucosal cells could lead an increase of pro-inflammatory cytokines TNF-α and IL-6, that in turn stimulate tumorigenesis. It is also demonstrated that IL-6 enhanced both initiation and progression of tumorigenesis and that STAT3 activated IL-6 which plays an essential role in colonic mucosal regeneration after injury and during tumorigenesis. High levels of TNF-α and IL-6 and activation of NF-κB/IL-6/STAT3 pathway are greatly increased in the patients with UC and colonic cancer (32) . Furthermore, a reciprocal regulation of ER stress and UC was found in which pro-inflammatory stimuli (i.e cytokines) trigger ER stress, which in turn further initiates or amplifies inflammatory responses. In this study, M10 strongly prevented the ER stress-induced reciprocal regulation of ER stress and chronic inflammation, thus preventing the inflammation-driven colorectal tumorigenesis.
In conclusion, oral administration of M10 exerts chemopreventative effect on UC and colorectal tumor in mice. The mechanism of chemoprevention is associated with reduction of biomarkers in inflammation, proliferation and autophagy through inhibiting robust ER stress in colorectal epithelial cells. These results justify further evaluation of M10 in clinical trials.
Supplementary material
Supplementary Data can be found at Carcinogenesis online.
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